PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Rhea-AI Summary

PolyPid to present SHIELD I Phase 3 clinical data for D-PLEX100 at American College of Surgeons Clinical Congress 2023

Positive

• PolyPid will present the SHIELD I Phase 3 clinical data for D-PLEX100 at the American College of Surgeons Clinical Congress 2023. The presentation will highlight the impact of locally applied Doxycycline-Eluting Drug (D-PLEX) on the incisional infection rate in elective colorectal surgery. The abstract will be available on www.polypid.com after the conference.

Negative

• None.

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX₁₀₀ will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

American College of Surgeons Clinical Congress 2023

Presentation Title:	Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial
Presenter:	Shmuel Sharoni, M.D.
Date/Time:	October 23, 2023/4:15 PM - 5:45 PM Eastern Time
Location:	Session SF120 – Colon and Rectal Surgery I BCEC Ballroom East, Level 3

The abstract will be available on www.polypid.com once the conference concludes.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

What is the purpose of the presentation?

The presentation aims to highlight the impact of D-PLEX100 on the incisional infection rate in elective colorectal surgery.

Where and when will the presentation take place?

The presentation will take place at the American College of Surgeons Clinical Congress 2023 on October 23, 2023, from 4:15 PM to 5:45 PM Eastern Time.

Where can I find the abstract?

The abstract will be available on www.polypid.com after the conference.